Checked, not settled
Checks out so far.
“In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls.”
2 of 4 review checks done · 1 counted · 1 by the author only
Supported · 0.9908 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.
Share:
Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else
“In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in…”
https://galedra.org/claims/78de54be-827c-8f56-8c80-fecdff28a421/card
Or just the link: https://galedra.org/claims/78de54be-827c-8f56-8c80-fecdff28a421/card
See the evidence · 
Galedra